Shire Continues To Grow HAE Franchise With Takhzyro, As Hemophilia Takes A Hit

Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.